Thymic egress: S1P of 1000 by Zachariah, Marcus A & Cyster, Jason G
Thymic egress: S1P of 1000
Marcus A Zachariah and Jason G Cyster*
Address: Howard Hughes Medical Institute and Department of Microbiology and Immunology, University of California at San Francisco,
513 Parnassus Avenue, San Francisco, CA 94143, USA
*Corresponding author: Jason G Cyster (jason.cyster@ucsf.edu)
F1000 Biology Reports 2009, 1:60 (doi:10.3410/B1-60)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Biology/content/1/60
Abstract
Recent studies have begun to illuminate the mechanism of T-cell export from the thymus, with the
identification of a required lysophospholipid receptor, two upstream transcription factors, and
several downstream regulators of cytoskeleton dynamics. This work has generated immediate
translational impact, aiding the design of immunosuppressant drugs and the identification of a novel
form of human immunodeficiency.
Introduction and context
Human immunocompetence and survival depend on
the egress of newly produced T cells from the thymus.
Approximately 1% of the thymocyte population emi-
grates from the thymus each day to populate the
peripheral T-cell compartment [1]. Following the arrival
of early thymic progenitors, the thymus supports all
steps of T-cell development, from the differentiation of
progenitors into T-cell receptor (TCR)-expressing CD4
and CD8 double-positive (DP) cells in the cortex to the
maturation of DP into CD4 or CD8 single-positive (SP)
cells that localize to medullary regions. SP thymocytes
initially possess an immature phenotype but over time
acquire markers associated with maturation (Figure 1).
Egress is thought to occur via blood vessels and
lymphatics, but the route that predominates remains
unknown [2,3]. An initial insight into the mechanism of
thymic egress came with the finding that transgenic
expression in thymocytes of pertussis toxin, an inhibitor
of Gai signaling, strongly inhibited egress [4]. A role for
Gai2 in thymocyte emigration was later suggested [5]
though may instead reflect an accelerated transition of
Gai2-deficient cells from the DP to SP stage of develop-
ment [6]. Important further advances regarding the
mechanism of thymic egress emerged from a combina-
tion of pharmacological and genetic studies that esta-
blished an essential role for sphingosine-1-phosphate
(S1P) and one of its G-protein-coupled receptors.
Major recent advances
The compound FTY720, identified during a screen for
immunosuppressants, blocks thymic egress [7]. The
active phosphoryl metabolite of FTY720 acts as an
agonist for four of five S1P receptors [8], and of these,
S1P1 is strongly upregulated in maturing SP thymo-
cytes [9]. Remarkably, genetic deletion of S1P1 in
thymocytes phenocopied the pertussis transgenic
mouse, indicating that S1P1 is the primary Gi-coupled
receptor mediating egress [9,10]. Deficiency in the two
kinases that generate S1P led to a similar thymic egress
defect [3]. A second small molecule, 2-acetyl-4-tetra-
hydroxybutyl-imidazole (THI), known to reduce thy-
mic egress when fed to mice [11], was found to inhibit
S1P lysase, causing 1,000-fold increases in thymic S1P
and down-modulation of thymocyte S1P1 [12]. Similar
findings were made when S1P lyase was knocked down
using a short hairpin RNA (shRNA) [12] and through
analysis of mice lacking the S1P lyase gene [13]. The
latter mice showed severe growth abnormalities and
poor viability, perhaps reflecting roles of the lyase in
sphingolipid metabolism, and thymic function was
strongly affected. Introduction of a low-expressing S1P
lyase transgene rescued non-lymphoid pathologies
while failing to fully restore thymic egress [13]. These
studies highlight the importance of appropriately
compartmentalized S1P distribution to support normal
thymic egress (Figure 1).
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compartment in mice lacking Krüppel-like factor-2
(KLF2), a zinc-finger transcription factor, revealed a
block in thymic egress associated with reduced S1P1
mRNA in mature thymocytes [14]. KLF2 co-immuno-
precipitated with the proximal S1P1 promoter and could
transactivate the promoter. However, sufficient S1P1
may remain in KLF2-deficient cells to permit low
amounts of thymic egress [15] and further work will be
needed to fully define the factors controlling S1P1
expression. Insight into factors that act upstream of
KLF2 has come from work on the Foxo family of
transcription factors. Foxo1 promotes expression of KLF2
and, likely in turn, S1P1 [16]. Deficiency in Foxo1 led to
a slight accumulation of mature SP thymocytes, particu-
larly of the CD8 lineage [17], though the block was less
severe than for KLF2 deficiency. Other Foxos appear
likely to help drive KLF2 expression. The inhibition of
Foxo transcription factors by phosphoinositide 3-kinase
(PI3K) signaling [16] might explain the thymic egress
block seen in transgenic mice overexpressing PI3K in
thymocytes [18].
The factors determining when expressions of Foxo, KLF2,
and thus S1P1 are turned on remain undefined, but
recent work suggests the involvement of a timer
mechanism. In transgenic mice expressing green fluor-
escent protein (GFP) from the Rag2 locus, the amounts
of GFP in the cell can be used as a molecular timer to
determine how much a thymocyte has aged since its
Rag2-expressing DP stage of development [19,20]. By
means of this approach, a medullary dwell time for SP
thymocytes of 4 to 5 days was calculated, with egress
occurring in a ‘conveyor belt’ fashion with cells that enter
the medulla first exiting the thymus first [20].
To exit the thymus, T cells must reverse-transmigrate
across an endothelial barrier. Several recent observations
suggest that molecules required for reorganization of the
thymocyte actin cytoskeleton are central to this process.
One study followed up on the description of a
spontaneous mutant mouse line with a thymic egress
defect and peripheral T-cell deficiency [21] to identify a
role for the Arp2/3 regulatory protein coronin-1A in
thymic egress [22]. Notably, although DP cell migration
was also affected by the mutation when tested in vitro, the
in vivo thymic defect revealed itself only as an accumula-
tion of mature SP cells, suggesting an especially stringent
need for appropriate control of actin branching during
the transmigration step. Mice deficient in the formin
protein, mDia1, also suffered reduced thymic egress [23].
Since formins support polymerization of unbranched
actin, this work further highlights the necessity of fine
actin cytoskeleton control to coordinate the cell shape
changes required for egress.
In addition to molecules involved in cytoskeletal
reorganization, cell adhesion molecules may play a role
in thymocyte egress. Recent data suggest that P-selectin
glycoprotein ligand-1 (PSGL-1) may be involved [24].
P-selectin marks a subset of thymic endothelial cells, and
thymocytes express PSGL-1 [24]. However, the accumu-
lation of thymocytes at the immature SP stage in PSGL-1-
deficient mice [24] is unusual for a thymic egress defect
(Figure 1). Further study of how PSGL-1 influences SP
thymocyte behavior is needed before it can be concluded
to function at the egress step.
Figure 1. Thymocyte maturation and egress via a blood vessel
A thymocyte is depicted undergoing maturation from the cortical CD4 and
CD8 double-positive (DP) stage to the medullary CD4 single-positive (SP)
stage. The SP cell is initially in an immature state, lacking Krüppel-like factor-
2 (KLF2) and sphingosine-1-phosphate receptor-1 (S1P1) and having a
characteristic surface phenotype. After a period of a few days, if the cell
survives negative selection, it upregulates KLF2 and then S1P1 (green
7-transmembrane structure) and undergoes other changes in surface
marker expression. Acquisition of S1P1 allows the cell to respond to S1P
(green dot) that is present at approximately 1,000 nM in the vessel lumen
(supplied by red blood cells) and locally supplied by radiation-resistant cells,
perhaps endothelial cells or pericytes. Thymic pericytes are unusual in being
neural crest cell (NCC)-derived. The final egress step triggered by S1P,
likely the reverse transmigration step, requires coronin-1A- and mDia1-
mediated reshaping of the actin cytoskeleton and thus the cell. Cells that
have just exited the thymus are referred to as recent thymic emigrants
(RTEs). T cells that are genetically deficient in S1P1 or KLF2 can reach the
mature SP stage but then fail to egress and accumulate in the medulla.
Treatment with FTY720 or with S1P lyase inhibitors that promote increases
in intrathymic S1P causes S1P1 down-modulation from the cell surface and
likely degradation (black crosses) and interrupts egress, again causing
accumulation of mature SP cells in the medulla. Cells lacking coronin-1A or
mDia1 are also egress-defective. imm, immature, mat, mature.
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involves a layer of pericytes and two layers of basement
membrane, the latter forming the so-called perivascular
s p a c e( P V S )[ 2 ] .T h es i g n i f i c a n c eo ft h eP V Si ne g r e s s
remains unclear, though a reconstitution study has
correlated the appearance of SP thymocytes in the PVS
with the time when cells begin to egress from the thymus
[25]. Two recent studies made the striking observation that
the pericytes surrounding thymic blood vessels are neural
crest cell-derived [26,27]. The significance of this specia-
lizedoriginforthymicpericytesisunknownbutmayrelate
to the barrier properties of thymic vessels [28] or to their
unique requirement to support thymocyte egress.
Future directions
Our current understanding of T-cell egress has profited
enormously from the discovery of the egress inhibitory
drug, FTY720, and the potential of this molecule for
treatment of human autoimmune disorders is under
ongoing investigation [29]. The immunosuppressive
potential of S1P lyase inhibition is also under explora-
tion with a small molecule inhibitor, LX2931, entering
clinical trial [30]. An important question in this area will
be to define the impact of prolonged inhibition of
thymic egress on thymic function.
The importance of normal thymic egress in humans has
also been highlighted by the identification of a T
−B
+
natural killer (NK)
+ severe combined immune deficiency
(SCID) patient who lacked functional alleles of the
coronin-1A gene [22]. Unusual for T
−B
+NK
+SCID but
consistent with a thymic egress defect, the patient
possessed normal thymic mass [31]. Given that the
coronin-1A gene resides in a region of the human
genome subject to copy number variation, it seems likely
that further cases of SCID resulting from deficiency in
this gene will be identified.
Work over the last several years has led to an increasingly
detailed model for the essential final step in thymocyte
maturation, acquisition of egress competence, but many
questions remain. Chief among these are identifying the
precise locationand cellular dynamics ofthymocyteegress,
understanding how KLF2 induction is triggered over time,
and establishing whether alterations in thymic egress occur
as part of the change in thymic function that takes place in
certain infectious and autoimmune diseases and during
aging. Given the translational advances that have already
been made, we can be sure that further research on thymic
egress will continue to impact human medicine.
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